OncLive TV

Akriti Jain, MD, discusses the outcomes of the phase 3 COMMANDS trial in transfusion-dependent lower-risk myelodysplastic syndromes.

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

Sarah Sammons, MD, discusses the real-world incidence of brain metastases in HER2-positive breast cancer per line of treatment as well as cumulatively.

Joseph Mikhael, MD, discusses the importance of closing gaps in care for patients with multiple myeloma in underserved populations.

Balazs Halmos, MD, discusses treatment strategies for patients with EGFR-mutant non–small cell lung cancer.

David Samuel Dicapua Siegel, MD, discusses the importance of closing the gaps in cancer care and spreading awareness of current treatment inequities in oncology through campaigns such as World Cancer Day.

Wally Curran, MD, discusses current and developing treatment strategies for patients with stage III unresectable non–small cell lung cancer.

George Simon, MD, FACP, FCCP, discusses the importance of enrolling diverse patient populations in cancer clinical trials.

Benjamin Levy, MD, discusses the mechanism of action of antibody-drug conjugates in patients with non–small cell lung cancer.

Ticiana Leal, MD, discusses the variety of DLL3-targeted agents in development for patients with small cell lung cancer and neuroendocrine tumors.

Bruna Pellini, MD, discusses the importance of developing circulating tumor DNA assays with increased sensitivity.

Estelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.

Daniel J. George, MD, discusses the phase 3b CheckMate 8Y8 study of nivolumab plus ipilimumab vs nivolumab alone in previously untreated advanced RCC

Jorge J. Castillo, MD, discusses preliminary data from a phase 2 study of acalabrutinib plus rituximab in patients with IgM symptomatic anti-MAG peripheral neuropathy.

James Yu, MD, discusses the validation of the ARCAD nomogram in the real-world setting for patients with stage IV colorectal cancer.

John Michael Bryant, MD, discusses the effects of germline DNA repair mutations on radiosensitivity in patients with pancreatic ductal adenocarcinoma.

Rona Yaeger, MD, discusses the rationale for launching an expansion cohort study based on findings from the CodeBreaK 101 study.

Billy Truong discusses the rationale for investigating the functions of ERK2 substrate binding modalities in patients with myeloproliferative neoplasms.

Janaki Neela Sharma, MD, discusses data with triplet therapies in patients with hormone-sensitive prostate cancer.

Sarah Crafton, MD, discusses the potential future of antibody-drug conjugates in patients with ovarian cancer.

Maria Hafez, MD, discusses differences in biomarker expression prior to and following neoadjuvant chemotherapy treatment in HER2-positive breast cancer.

Emily Arner, PhD, discusses research on the role of SETD2 loss in metastatic clear cell renal cell carcinoma ccRCC.

John Mascarenhas, MD, discusses the use of selinexor with ruxolitinib in JAK inhibitor–naive myelofibrosis, highlighting the phase 2 XPORT-MF-044 trial

Benjamin Garmezy, MD, discusses the impact of frontline combination regimens on patient outcomes in patients with renal cell carcinoma.

Nicholas P. McAndrew, MD, MSCE, discusses the implications of the phase 2 PHERGain study of chemotherapy de-escalation in patients with HER2-positive early breast cancer.

Jorge J. Castillo, MD, discusses the efficacy of treatment with iopofosine I 131 in patients with Waldenström macroglobulinemia.

Hamza Hashmi, MD, discusses a real-world study of the efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma.

Robert DeBernardo, MD, discusses the current role of PARP inhibitors in the frontline treatment landscape in ovarian cancer.

Minoo Battiwalla, MD, discusses findings from a study of outpatient care after CAR T-cell therapy in patients with hematologic malignancies.

Christos Kyriakopoulos, MD, discusses data from a phase 1/2 study of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer.